Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in weight loss trials. Zepbound targets adults with obesity and comorbidities.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in weight loss trials. Zepbound targets adults with obesity and comorbidities.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing